DWP
NBIX icon

Daymark Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Daymark Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$687K Buy
5,217
+3,436
+193% +$456K 0.02% 355
2025
Q4 		$253K Sell
1,781
-127
-7% -$18.4K 0.01% 530
2025
Q3 		$268K Sell
1,908
-37
-2% -$5.01K 0.01% 510
2025
Q2 		$244K Buy
+1,945
New +$223K 0.01% 493
2025
Q1 		– Sell
-1,786
Closed -$244K – 520
2024
Q4 		$244K Buy
+1,786
New +$221K 0.01% 450
2024
Q3 		– Sell
-1,774
Closed -$244K – 523
2024
Q2 		$244K Buy
1,774
+274
+18% +$37.6K 0.01% 444
2024
Q1 		$207K Buy
+1,500
New +$205K 0.01% 412

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Daymark Wealth Partners's NBIX Position: Q1 2026 in Review

Daymark Wealth Partners increased its Neurocrine Biosciences (NBIX) stake by 193% in Q1 2026, buying an estimated $456K and bringing the position to 5,217 shares worth $687K. The position accounts for 0.02% of the portfolio, ranked #355.

Daymark Wealth Partners first reported a position in NBIX in Q1 2024 and has held it in 7 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Daymark Wealth Partners held 5,217 shares of Neurocrine Biosciences worth $687K as of Q1 2026.
  • Daymark Wealth Partners bought 3,436 Neurocrine Biosciences shares in Q1 2026, an estimated $456K.
  • Neurocrine Biosciences made up 0.02% of Daymark Wealth Partners's portfolio in Q1 2026, its #355 holding.
  • Daymark Wealth Partners first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 7 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Daymark Wealth Partners's 13F filing for Q1 2026, filed 11 May 2026.